Chronic hepatitis D

Close metadata

Recommended articles:

Perspective directions in the treatment of polycystic ovary syndrome (literature review). Russian Journal of Human Reproduction. 2024;(3):94-104

Late-onset schizophrenia and schizophrenia-like psychosis with very late onset. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):32-40

Modern pathogenetic treatment of rare demyelinating diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):33-36

Mistakes in the diagnosis of neuromyelitis optic spectrum diseases lead to wrong therapy and deterioration of patients’ condition. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):96-100

Effectiveness of clinical recommendations: treatment outcomes in patients with immune thrombocytopenia. Medical Technologies. Assessment and Choice. 2024;(3):62-69

Modern aspects of etiopathogenesis, diagnosis and treatment of lipedema. Plastic Surgery and Aesthetic Medicine. 2024;(3):86-92

Preferable drugs for relief of migraine attacks and tension type headache in pregnant women. Russian Journal of Pain. 2024;(3):12-18

Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):51-59

Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy. P.A. Herzen Journal of Oncology. 2024;(5):76-81

Quality assessment of health care delivery to patients with sexually transmitted infections in dermatovenereological institutions of Moscow according to medical records analysis. Russian Journal of Clinical Dermatology and Venereology. 2024;(5):503-509

Aim. The present review was designed to summarize the current views of the main characteristics of hepatitis D virus (HDV), the prevalence of this pathology, and prospects for the treatment of chronic HDV infection. Conceptual issues. It is believed that around 15 million people all over the world are infected with hepatitis D virus; this figure amounts to approximately 15% of all the patients presenting with hepatitis B (HBV). Russia ranks among the countries with a high prevalence of HDV infection. The patients with chronic hepatitis D are characterized by a more severe clinical course of the disease, faster development of liver cirrhosis, higher risks of hepatocellular carcinoma, and more frequent decompensation of liver cirrhosis in comparison with the patients presenting with chronic hepatitis B in the absence of the D-agent. Conclusion. Interferon-alpha (IFN-a) thus far remains the sole officially approved medication with antiviral properties for the treatment of chronic hepatitis D infection. The effectiveness of IFN-a therapy does not exceed 20-25%. At present, Myrcludex B and Lonafarnib are considered to provide a promising tool for the management of chronic hepatitis D infection.

Keywords:

hepatitis D

treatment

therapy

interferon therapy

Myrcludex B and Lonafarnib

Authors:

Galimova S.F.

PAO «Klinika К+31», Moscow, Russian Federation

List of references:

Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73-85. doi:10.1016/s0140-6736(10)61931-9.
Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13 year prospective study. J Hepatol. 2013;59:949-59. doi:10.1016/j.jhep.2013.07.005.
Rizzetto M. The delta agent. Hepatology. 1983;3(5):729-737. doi:10.1002/hep.1840030518.
Taylor JM. Virology of hepatitis D virus. Sem Liver Dis. 2012;32:195-200. doi:10.1055/s-0032-1323623.
Hadziyannis SJ. REVIEW: Hepatitis delta. J Gastroenterol Hepatol. 1997;12:289-298. doi:10.1111/j.1440-1746.1997.tb00424.x.
Wedemeyer H, Hepatitis D — Diagnosis and Treatment. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology 2015. A Clinical Textbook. www.hepatologytextbook.com. р. 182-201.
Lamers MH, Kirgiz OO, Heidrich B, Wedemeyer H, Drenth JP. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012;17:1029-1037. doi:10.3851/imp2306.
Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87-97. doi:10.1002/hep.27102.
Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740-1749. doi:10.1053/j.gastro.2004.03.017.
Koh С, Canini L, Dahari H, Zhao X, Uprichard S, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Thanda Han MA, Scott JC. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. The Lancet Infectious Diseases. 2015;15(10):1167-1174. doi:10.1016/s1473-3099(15)00074-2.
Lütgehetmann M, Mancke LV, Volz T et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685-694. doi:10.1002/hep.24758.
Bogomolov P, Voronkova N, Buyeverov A, Matsievich M, Alexandrov A., Wedemeyer H. The first experience of application of Myrcludex B at chronic hepatitis D (the pilot study). Clinical prospects in Gastroenterology, Hepatology. 2015;2:22-26. (In Riss.)
Rizzetto, M., Canese M.G, Arico S, Crivell O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen—antibody system (delta/anti—delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997-1003. doi:10.1136/gut.18.12.997.
Taylor JM. Virology of hepatitis D virus. Sem Liver Dis. 2012;32(03):195-200. doi:10.1055/s-0032-1323623.
Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73-85. doi:10.1016/s0140-6736(10)61931-9.
Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol. 2006;307:151-171. doi:10.1007/3-540-29802-9_8.
Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, Lee PC, Lee SD, Wu JC. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130:1625-1635. doi:10.1053/j.gastro.2006.01.035.
Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, Markova A,, Bremer B, Schlaphoff V, Cornberg M, Manns M.P, Sandberg J.K, Ljunggren H-J, Bjorkstrom N.K., Wedemeyer H. Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis. J Infect Dis. 2014;209:1362-1373. doi:10.1093/infdis/jit561.
Nakano T, Shapiro CN, Hadler SC, Casey JL, Mizokami M, Orito E et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol. 2001;82(Pt 9):2183-2189.
Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228-236. doi:10.1055/s-0032-1323628.
Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;28:494-498. doi:10.1111/j.1478-3231.2008.01673.x.
Romeo R, Del Ninno E, Rumi M, Russo А, Sangiovanni А, Franchis R, Ronchi G, Colomboet M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629-1638. doi:10.1053/j.gastro.2009.01.052.
Niro GA, Smedile A, Ippolito AM, Ippolito, Ciancio А, Fontana R, Olivero A, Valvano MR, Abate LM, Gioffreda D, Caviglia PG, Rizzetto M, Andriulliet A. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53(5):834-840. doi:10.1016/j.jhep.2010.06.008.
Butí M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, Sauleda S, Tabernero D, Schaper M, Esteban R. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18:434-442. doi:10.1111/j.1365-2893.2010.01324.x.
Braga WS, de Oliveira CM, de Araújo JR, Castilho Mda C, Rocha JM, Gimaque JB, Silva ML, Vasconcelos HL, Ramasawmy R, Paraná R. Chronic HDV/HBV co-infection: Predictors of disease stage — a case series of HDV-3 patients. J Hepatol. 2014;61(3):1205-1211. doi:10.1016/j.jhep.2014.05.041.
Calle-Serrano B, Manns MP, Wedemeyer H. Hepatitis Delta in HIV-infected individuals. Seminars in Liver Disease. 2012;32(2):120-129. doi:10.1055/s-0032-1316467.
Fernández-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, Soriano V. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549-1553. doi:10.1093/cid/ciu167.
Castellares C, Barreiro P, Martin-Carbonero L, Labarga P, Vispo ME, Casado R et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15:165-172. doi:10.1111/j.1365-2893.2007.00903.x.
Sheng WH, Hung CC, Kao JH, Kao JH, Chang SY., Chen MY, Hsieh SM, Chen PJ, Chang SC. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis. 2007;44:988-995. doi:10.1086/511867.
Calle-Serrano B, Großhennig A, Homs M et al. Development and Evaluation of a Baseline Event-Anticipation (BEA)-Score for Hepatitis Delta. Journal of Viral Hepatitis 2014; epub. (Development and evaluation of a baseline-event-anticipation score for hepatitis delta. Calle Serrano B, Großhennig A, Homs M, Heidrich B, Erhardt A, Deterding K, Jaroszewicz J, Bremer B, Koch A, Cornberg M, Manns MP, Buti M, Wedemeyer H. J Viral Hepat. 2014 Mar 27. doi:10.1111/jvh.
Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y et al. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther. 2012;17:305-312. doi:10.3851/imp1926.
Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG et al; HIDIT-2 Study Group. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One. 2014;9(7):e101002. doi:10.1371/journal.pone.0101002.
Zachou K, Yurdaydin C, Drebber U et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2010;30(3):430-437. doi:10.1111/j.1478-3231.2009.02140.x.
Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014;9(3):e92062. doi:10.1371/journal.pone.0092062.
Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009;16:883-894. doi:10.1111/j.1365-2893.2009.01144.x.
Heidrich B, C Serrano B, Idilman R, Kabaçam G, Bremer B, Raupach R et al. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome HBeAg-positive hepatitis delta. Liver Int. 2012:32:1415-1425. doi:10.1111/j.1478-3231.2012.02831.x.
Shih HH, Jeng KS, Syu WJ, Huang YH, Su CW, Peng WL et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis D virus. J Virol. 2008;82:2250-2264. doi:10.1128/jvi.02155-07.
Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology. 2014;60:1902-1910. doi:10.1002/hep.27357.
Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat. 2000;7:428-434. doi:10.1046/j.1365-2893.2000.00254.x.
Niro GA (a), Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005;22:227-232. doi:10.1111/j.1365-2036.2005.02542.x.
Garripoli A, Di Marco V, Cozzolongo R et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994;14:154-157. doi:10.1111/j.1600-0676.1994.tb00065.
Soriano V, Vispo E, Sierra-Enguita R, Mendoza Cd, Fernández-Montero JV, Labarga P, Barreiro P. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389-2394. doi:10.1097/qad.0000000000000417.
Niro GA (b), Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat. 2005;12:2-9. doi:10.1111/j.1365-2893.2005.00601.x.
Lau DT (a), Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999;117:1229-1233. doi:10.1016/s0016-5085(99)70409-9.
Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728-735. doi:10.1002/hep.21325.
Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713-720. doi:10.1002/hep.21296.
Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H et al. Pegylated interferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322-331. doi:10.1056/nejmoa0912696.
Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience. Antivir Ther. 2014;19:463-468. doi:10.3851/imp2728.
Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, McBurney R, Schmid P, Albrecht J, Kleiner DE, Ghany MG, Liang TJ, Hoofnagle JH. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93-104. doi:10.1111/apt.12788.
Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87-97. doi:10.1002/hep.27102.
Wedermeyer H, C Yurdaydin, S Ernst et al. Prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-a-2a plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: the HIDIT-2 study. 49thEuropean Association for the Study of the Liver International Liver Congress (EASL 2014). London, April 9—13, 2014. Abstract O4. doi:10.1016/s0168-8278(14)60006-4.
Schieck A, Schulze A, Gähler C et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts Hepatology. 2013;58:43-53. doi:10.1002/hep.26211.
Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: a review. World J Gastroenterol. 2013;5:666—675. doi:10.4254/wjh.v5.i12.666.
Chen PJ, Wu TC. One step closer to an experimental infection system for Hepatitis B Virus? The identification of sodium taurocholate cotransporting peptide as a viral receptor. Cell Biosci. 2013;3:2. doi:10.1186/2045-3701-3-2.
Kieran MW, Gordon LB, Kleinman ME. The role of the farnesyltransferase inhibitor lonafarnib in the treatment of Progeria. Expert Opinion on Orphan Drugs. 2014;2(1):95-105. doi:10.1517/21678707.2014.87202.
Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronicmyeloid leukemia in the chronic or accelerated phase that is resistant or refractory toimatinib therapy. Cancer. 2006;106(2):346-352. doi:10.1002/cncr.21590.
Eiger BioPharmaceuticals. Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV). Press release. April 27, 2015.
Yurdaydin C, Idilman R, Choong I, Kalkan C, Keskin O, Karakaya MF, Tuzun AE, Karatayli E, Bozdayi M, Cory D, Glenn JS. Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis. Journal of Hepatology. 2015;62:S252. Аbstract O118. doi:10.1016/s0168-8278(15)30137-9.
Koh C, Canini L, Dahari H, Cooper S, Cory D, Winters MA, Choong I, Cotler SJ, Kleiner DE, Yurdaydin C, Heller T, Glenn JS. Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection. Journal of Clinical Virology. 2015;69:247. doi:10.1016/j.jcv.2015.06.071.

Close metadata